End-of-study per-protocol analyses were performed after a mean follow-up of 28-30 mo for CAP and invasive pneumococcal disease ( IPD ) ( PHiD-CV , n = 10,211 ; control , n = 10,140 ) and AOM ( n = 3,010 and 2,979 , respectively ) .